CDHR5 Inhibits Proliferation of Hepatocellular Carcinoma and Predicts Clinical Prognosis

Overview

Journal Ir J Med Sci

Specialty General Medicine

Date 2019 Sep 5

PMID 31482521

Citations 4

Authors

Xue Ding

Xiaomin Tian

Wei Liu

Zijia Li

Affiliations

Soon will be listed here.

Abstract

Background: As one of the most prevalent malignancies, hepatocellular carcinoma (HCC) ranks the third leading cause of cancer death worldwide. Due to the lack of biomarkers for early diagnosis, the clinical outcome of HCC remains unsatisfied with the current common therapeutic approaches, including surgery and chemotherapies. Thus, sensitive biomarkers and targeted therapies are in great need.

Aims: In this study, we explored and verified whether CDHR5 (cadherin-related family member 5), a cadherin family protein, could serve as the potential biomarkers for HCC in the clinic.

Methods: A retrospective study which contained 154 HCC patients was performed. Chi-square was utilized to analyze the relationship between CDHR5 expression and the clinicopathological features of HCC patients. The Kaplan-Meier method and Cox regression analyses were then used to evaluate the survival of HCC patients. In addition, cell proliferation assay and colony formation assay were performed to examine the effects of CDHR5 on the progression of HepG2 and Huh7 cells.

Results: IHC and RT-qPCR revealed that CDHR5 was downregulated in HCC tissues compared with adjacent liver tissues. In addition, CDHR5 expression was significantly correlated with tumor numbers, tumor size, and TNM stage. CDHR5 expression was then shown to be an independent risk factor for survival of HCC patients by survival analysis. In vitro experiments showed that CDHR5 suppressed the proliferation capacity of HCC cells.

Conclusions: Taken together, our study not only identified CDHR5 as a novel prognostic biomarker in HCC but also provided evidence that CDHR5 can inhibit HCC cell proliferation.

Citing Articles

CircWDR78 inhibits the development of colorectal cancer by regulating the miR-653-3p/RGS4 axis.

Hao C, Pu Y, Li J, Zhong Z, Huang Z, Wang X J Cancer Res Clin Oncol. 2025; 151(2):66.

PMID: 39912944 PMC: 11802675. DOI: 10.1007/s00432-025-06092-2.

CircMMP11 as a prognostic biomarker mediates miR-361-3p/HMGB1 axis to accelerate malignant progression of hepatocellular carcinoma.

Zou Q, Zhang Y, Zhu D, Liu X, Wang C, Xiang H Open Med (Wars). 2023; 18(1):20230803.

PMID: 38025527 PMC: 10655683. DOI: 10.1515/med-2023-0803.

Genomic Profiling of Chinese Cervical Cancer Patients Reveals Prevalence of DNA Damage Repair Gene Alterations and Related Hypoxia Feature.

Wen H, Guo Q, Zhou X, Wu X, Li J Front Oncol. 2022; 11:792003.

PMID: 35071000 PMC: 8782566. DOI: 10.3389/fonc.2021.792003.

Multi-Omics Characterization of Inflammatory Bowel Disease-Induced Hyperplasia/Dysplasia in the / Mouse Model.

Han Q, Kono T, Knutson C, Parry N, Seiler C, Fox J Int J Mol Sci. 2021; 22(1).

PMID: 33396408 PMC: 7795000. DOI: 10.3390/ijms22010364.

Up-regulation of CDHR5 expression promotes malignant phenotype of pancreatic ductal adenocarcinoma.

Gao J, Wang M, Li T, Liu Q, You L, Liao Q J Cell Mol Med. 2020; 24(21):12726-12735.

PMID: 33025744 PMC: 7687006. DOI: 10.1111/jcmm.15856.

References

Li Z, Chim J, Yang M, Ye J, Wong B, Qiao L . Role of PCDH10 and its hypermethylation in human gastric cancer. Biochim Biophys Acta. 2011; 1823(2):298-305. DOI: 10.1016/j.bbamcr.2011.11.011. View

Liu H, Xu Y, Zhang Q, Li K, Wang D, Li S . Correlations between TBL1XR1 and recurrence of colorectal cancer. Sci Rep. 2017; 7:44275. PMC: 5353619. DOI: 10.1038/srep44275. View

Woo Y, Shin Y, Hwang J, Hwang Y, Lee S, Park E . Epigenetic silencing of the MUPCDH gene as a possible prognostic biomarker for cyst growth in ADPKD. Sci Rep. 2015; 5:15238. PMC: 4604459. DOI: 10.1038/srep15238. View

Wang C, Yu G, Liu J, Wang J, Zhang Y, Zhang X . Downregulation of PCDH9 predicts prognosis for patients with glioma. J Clin Neurosci. 2012; 19(4):541-5. DOI: 10.1016/j.jocn.2011.04.047. View

Losi L, Grande A . Involvement of μ-protocadherin in colorectal carcinogenesis: a promise for clinico-pathological evaluation. Histol Histopathol. 2013; 29(1):11-9. DOI: 10.14670/HH-29.11. View

Hou S, Du P, Wang P, Wang C, Liu P, Liu H . Significance of MNK1 in prognostic prediction and chemotherapy development of epithelial ovarian cancer. Clin Transl Oncol. 2017; 19(9):1107-1116. DOI: 10.1007/s12094-017-1646-x. View

Xu Y, Yang X, Li Z, Li S, Guo S, Ismail S . Sprouty2 correlates with favorable prognosis of gastric adenocarcinoma via suppressing FGFR2-induced ERK phosphorylation and cancer progression. Oncotarget. 2016; 8(3):4888-4900. PMC: 5354878. DOI: 10.18632/oncotarget.13982. View

Liu H, Xu Y, Zhang Q, Yang H, Shi W, Liu Z . Prognostic significance of TBL1XR1 in predicting liver metastasis for early stage colorectal cancer. Surg Oncol. 2017; 26(1):13-20. DOI: 10.1016/j.suronc.2016.12.003. View

Montorsi L, Parenti S, Losi L, Ferrarini F, Gemelli C, Rossi A . Expression of μ-protocadherin is negatively regulated by the activation of the β-catenin signaling pathway in normal and cancer colorectal enterocytes. Cell Death Dis. 2016; 7:e2263. PMC: 5143391. DOI: 10.1038/cddis.2016.163. View

10.

Goldberg M, Peshkovsky C, Shifteh A, Al-Awqati Q . mu-Protocadherin, a novel developmentally regulated protocadherin with mucin-like domains. J Biol Chem. 2000; 275(32):24622-9. DOI: 10.1074/jbc.M000234200. View

11.

Bujko M, Kober P, Statkiewicz M, Mikula M, Ligaj M, Zwierzchowski L . Epigenetic-Mediated Downregulation of μ-Protocadherin in Colorectal Tumours. Gastroenterol Res Pract. 2015; 2015:317093. PMC: 4417986. DOI: 10.1155/2015/317093. View

12.

Wang X, Zhang Q, Wang Y, Zhuang H, Chen B . Clinical Significance of Ubiquitin Specific Protease 7 (USP7) in Predicting Prognosis of Hepatocellular Carcinoma and its Functional Mechanisms. Med Sci Monit. 2018; 24:1742-1750. PMC: 5882160. DOI: 10.12659/msm.909368. View

13.

Zhang Q, Fan H, Zou Q, Liu H, Wan B, Zhu S . TEAD4 exerts pro-metastatic effects and is negatively regulated by miR6839-3p in lung adenocarcinoma progression. J Cell Mol Med. 2018; 22(7):3560-3571. PMC: 6010880. DOI: 10.1111/jcmm.13634. View

14.

Yu J, Koujak S, Nagase S, Li C, Su T, Wang X . PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene. 2008; 27(34):4657-65. PMC: 3013056. DOI: 10.1038/onc.2008.101. View

15.

Hazan R, Qiao R, Keren R, Badano I, Suyama K . Cadherin switch in tumor progression. Ann N Y Acad Sci. 2004; 1014:155-63. DOI: 10.1196/annals.1294.016. View

16.

Liu H, Zhang Q, Li K, Gong Z, Liu Z, Xu Y . Prognostic significance of USP33 in advanced colorectal cancer patients: new insights into β-arrestin-dependent ERK signaling. Oncotarget. 2016; 7(49):81223-81240. PMC: 5348388. DOI: 10.18632/oncotarget.13219. View

17.

Losi L, Parenti S, Ferrarini F, Rivasi F, Gavioli M, Natalini G . Down-regulation of μ-protocadherin expression is a common event in colorectal carcinogenesis. Hum Pathol. 2011; 42(7):960-71. DOI: 10.1016/j.humpath.2010.10.009. View

18.

Takeichi M . Cadherin cell adhesion receptors as a morphogenetic regulator. Science. 1991; 251(5000):1451-5. DOI: 10.1126/science.2006419. View

19.

Zhong X, Zhu Y, Mao J, Zhang J, Zheng S . Frequent epigenetic silencing of PCDH10 by methylation in human colorectal cancer. J Cancer Res Clin Oncol. 2012; 139(3):485-90. DOI: 10.1007/s00432-012-1353-5. View

20.

Zhang Y, Jia Q, Kadel D, Zhang X, Zhang Q . Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC). Med Sci Monit. 2018; 24:2735-2743. PMC: 5952809. DOI: 10.12659/MSM.907514. View